Abstract:Objective:To investigate the expression of cyclin-dependent kinase 12 (CDK12) protein in prostate cancer (PCa) cells and its relationship with clinicopathological characteristics.Methods:From January 2015 to October 2016, 89 PCa patients underwent radical resection of prostate cancer and 50 benign prostate hyperplasia (BPH) underwent transurethral resection of the prostate in our hospital were enrolled. The expression of CDK12 in two pathological specimens was detected by immunohistochemistry (IHC) staining, and the relationship between CDK12 protein and clinicopathological characteristics of PCa patients was analyzed. After the operation, 89 PCa patients were followed up for 3 years, and were divided into survival group and death group according to the survival status. COX single factor and multifactor analysis were performed to summarize the risk factors affecting the prognosis of PCa patients. According to the CDK12 protein expression results, 89 PCa patients were divided into positive and negative groups, and survival curves were drawn to compare the 3-year survival status of two groups.Results:The positive expression rate of CDK12 protein in PCa tissue was significantly higher than that in BPH tissue ( P<0.05). The positive expression level of CDK12 protein had no significant difference among PCa patients with different ages ( P<0.05), while had significant difference among PCa patients with different prostate specific antigen (PSA) levels, Gleason scores and tumor stages ( P<0.05). Correlation analysis indicated that PSA level, Gleason score and tumor stage of PCa patients were positively correlated with positive CDK12 protein expression ( P<0.05). Three-year telephone and out-patient follow-up review showed that 33 PCa patients died and 56 survived. COX univariate analysis showed that there were significant differences between the survival group and the death group in PSA, Gleason score, tumor stage, and CDK12 protein expression status ( P<0.05). COX multivariate analysis indicated that PSA level>20 μg/L, Gleason score>7, tumor stage of T3, and positive expression of CDK12 protein were all independent risk factors that affected the prognosis of PCa patients. Survival curve found that 3-year survival rate of patients with CDK12 positive expression was significantly different from those of negative expression ( χ2=5.912, P<0.05). Conclusions:Over-expression of CDK12 protein may play an important role in the occurrence and development of PCa, and its positive expression level may be positively correlated with the degree of disease malignancy. Therefore, the study of CDK12 positive expression level has potential value in the assessment of the risk of PCa progression and the formulation of clinical treatment plans. Moreover, CDK12 expression is also a key factor affecting the prognosis of PCa patients.

CDK12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancer

CDK12: A Potent Target and Biomarker for Human Cancer Therapy

Cyclin-dependent Kinase Inhibition and Its Intersection with Immunotherapy in Breast Cancer: More Than CDK4/6 Inhibition

Integrative study reveals the prognostic and immunotherapeutic value of CD274 and PDCD1LG2 in pan-cancer

CDK1 Acts as a Prognostic Biomarker Associated with Immune Infiltration in Pan-Cancer, Especially in Gastrointestinal Tumors

Development of CDK12 as a Cancer Therapeutic Target and Related Inhibitors

A multidimensional Pan-cancer analysis of CDKN1A identifies CDKN1A as an Immunological and Prognostic Biomarker

The Prevalence of CDK12 Alterations in Chinese Cancer Patients and the Association with Tumor Mutation Burden(tmb) and Survival.

A pan-cancer analysis of potassium channel tetramerization domain containing 12 in human cancer

An Integrative Human Pan-Cancer Analysis of Cyclin-Dependent Kinase 1 (CDK1)

CDK12 Promotes Cervical Cancer Progression through Enhancing Macrophage Infiltration

CDK12 loss inhibits cell proliferation by regulating TBK1 in non-small cell lung cancer cells

CDK16 as a potential prognostic biomarker correlated with an immunosuppressive tumor microenvironment and benefits in enhancing the effectiveness of immunotherapy in human cancers

Targeting CDK12 for Cancer Therapy: Function, Mechanism, and Drug Discovery

Protocadherin-1 Serves As a Prognostic Biomarker and Promotes Pancreatic Cancer Progression by Suppressing CD8+ T Cell Infiltration Through CCL5-CCR5 Axis.

Targeting CDK12 Obviates the Malignant Phenotypes of Colorectal Cancer Through the Wnt/β-catenin Signaling Pathway

Expression of CDK12 protein in prostate cancer cells and its relationship with clinicopathological characteristics

Clinical significance of cyclin-dependent kinase inhibitor 2C expression in cancers: from small cell lung carcinoma to pan-cancers

CDKs Functional Analysis in Low Proliferating Early-Stage Pancreatic Ductal Adenocarcinoma.

CDCA8, a mitosis-related gene, as a prospective pan-cancer biomarker: implications for survival prognosis and oncogenic immunology

Comprehensive Analysis Revealed that CDKN2A is a Biomarker for Immune Infiltrates in Multiple Cancers